Angiogenesis
Angiogenesis (also known as neovascularization) is the generation of new blood vessels from pre-existing vasculature. It is a normal process in growth and development and is required for the formation of arteries, veins, and capillaries in an embryo.Angiogenesis has become an important target for cancer research with the recognition that it is one of the critical events necessary for cancer growth and metastasis. As a tumor develops, its size is limited by the diffusion of metabolites from existing blood vessels. Tumor angiogenesis, the growth of the new blood vessels, is essential for cancerous tumors to keep growing and spreading.As a tumor grows, cells at the center become starved of oxygen, inducing the expression of a transcription factor - hypoxia inducible factor-1 (HIF-1) - which upregulates the expression of a range of angiogenic factors. Growth factor signaling also initiates HIF-1 activity, pre-empting the need for growing cells to maintain oxygen homeostasis. As a result, HIF-1 itself has been isolated as a therapeutic target for cancer. More than a dozen different proteins, as well as several smaller molecules, have been identified as angiogenic meaning that they are released by tumors as signals for angiogenesis. Inhibitors of angiogenesis (antiangiogenics) are currently the focus of intense cancer research.As well as its detrimental effects in tumor growth and inflammatory disorders, the generation of new blood vessels is a vital process in the context of stroke, cardiovascular disease and diabetes. Many of the pathologies associated with diabetes, such diabetic neuropathy, reduced wound healing and diabetic ulcers, are caused by a reduced blood supply to the downstream tissue. Therefore, promoting angiogenesis in diabetic patients may represent an important strategy in reducing morbidity. Recent work using adenovirus-mediated transfer of VEGF165 showed that promoting angiogenesis significantly accelerated wound healing.
Angiogenesis Products Targets
Products for Angiogenesis - Page 2
- Cat.No. Product Name Information/Activity
-
BCC1287
P005091
P005091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with an EC50 of 4.2 μM.
-
BCC6275
P11
848644-86-0
-
BCC2436
PX 12
PX-12(IV-2) is an irreversible inhibitor of Thioredoxin-1 (Trx-1); inhibits the growth of MCF-7 and HT-29 cells with IC50 values of 1.9 and 2.9 μM, respectively.
-
BCC1879
R1530
R1530 is the multikinase inhibitor with potential antiangiogenesis and antineoplastic activities.
-
BCN5607
Resveratrol
Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor.
-
BCC2248
Thalidomide
Thalidomide is initially promoted as a sedative, inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ∼250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.
-
BCC2514
Tranilast
Tranilast is an antiallergic agent.
-
BCC7568
XRP44X
729605-21-4
-
BCC2520
AEE788 (NVP-AEE788)
AEE788 is an inhibitor of the EGFR and ErbB2 with IC50 values of 2 and 6 nM, respectively.
-
BCC1051
AG-18
Tyrphostin 23 (Tyrphostin A23) is an EGFR inhibitor with an IC50 and Kiof 35 and 11 μM, respectively.


